UK healthcare has pilot blood tests that can detect 50 types of cancer

The Galerie blood test, developed by California-based healthcare company Grill, will be performed with 165,000 patients, which the NHS described as a “world-first deal” in a news release on Friday.

Grill, whose work focuses on early detection of cancer, has been supported by investors including tech billionaire Bill Gates and Amazon founder Jeff Bezos.

NHS England expects the blood test to be particularly useful in identifying those types of cancer that are currently difficult to diagnose and treat early.

NHS chief executive Simon Stevens said “early detection – particularly for the treatment of difficult conditions such as ovarian and pancreatic cancer – has the potential to save many lives.”

He said that more than 1,000 people are diagnosed with cancer every day in the UK.

Why is pancreatic cancer so deadly

Starting in mid-2021, the pilot program will include 165,000 people, including 140,000 people aged 50 to 79 who have no symptoms but will have an annual blood test in three years.

The news release stated that the remaining 25,000 participants would be people with potential symptoms of cancer, who would be offered blood tests to speed up their diagnosis after being referred to the hospital in the usual way.

NHS England said the results were expected to arrive by 2023, after which it is expected that by 2025, a million people can receive the test.

A news release said that about half of all cancers in England are currently diagnosed at stage one or two, but the NHS aims to increase that to three quarters by 2028.

Grill said in a press release that, according to modeling data, “incorporating galleries into existing standard care reduces the ability to diagnose cancer by nearly half as late, leading to cancer deaths in the UK The total number may be reduced. ” About one-fifth. “

According to the charity Cancer Research UK, five-year survival for cancer in the UK is lower than the European average.

Lawrence Young, professor of molecular oncology at the University of Warwick, said the Galerie test was one of several novel blood tests being developed to detect cancer at a very early stage when it is more easily treated.

Experimental blood test detects cancer in people who did not know it

“There are several trials evaluating this approach and a publication from the Association of Circulating Cell-Free Genome Atlas (CCGA) examining the Galerie trial in 6,689 participants produced very encouraging results for more than 50 different cancers at different stages of development Are “he told Science Media Center.

However, not all cancer experts agree that the NHS should conduct a gallery blood test.

Paul Farroha, a professor of cancer epidemiology at the University of Cambridge, told the Science Media Center that he was skeptical about the pilot’s scientific basis based on available published research.

“The Galerie blood test is a test that may be able to detect cancer in the blood in individuals with early cancer, although it effectively does that the evidence is weak,” he said. “The NHS should not invest in such testing before it is adequately evaluated in well-run, large-scale clinical trials.”

Michelle Mitchell, Chief Executive Officer of Cancer Research UK, said the tests developed by Grill had “great transformational potential” if they proved effective in detecting cancer first.

Head of Early Diagnosis at Cancer Research UK Dr. Jodi Moffat said the results so far from studies outside the UK were promising. “But the sample size, especially for some cancer types, has been very small and therefore it needs to be tested in a much larger sample, and patients have a positive follow-up test with blood tests with long-term follow-up testing. Not to find out where this cancer is missing, ”she told the Science Media Center.

“Based on the evidence we have seen, we are currently not good at taking test I cancer where it is small and has not spread to other parts of the body.”

CNN’s Amy Cassidy and Sarah Diab contributed to this report.


Leave a Reply